Xenetic Biosciences Updates Investor Presentation on Santersus Exchange

What Happened
Xenetic Biosciences, Inc. filed a Form 8-K on September 23, 2026 reporting a Regulation FD disclosure: the company released an updated investor presentation related to its pending share exchange transaction with Santersus AG, which Xenetic first announced on September 16, 2026. The updated presentation is attached as Exhibit 99.1 to the filing and is dated September 2026.

Key Details

• Filing date: September 23, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Subject: Updated investor presentation concerning the pending share exchange with Santersus AG (previously announced Sept 16, 2026).
• Exhibit: Investor Presentation (Exhibit 99.1), dated September 2026, included with the filing.
• The filing does not disclose new financial statements or definitive transaction terms in this 8-K.

Why It Matters
The updated presentation provides investors with the company’s current messaging and material details about the proposed share exchange with Santersus AG, which can help assess strategic direction and potential impact on shareholders. However, this 8-K is a disclosure of presentation materials under Regulation FD—not a filing of definitive transaction agreements or financial results—so investors should watch for subsequent filings (e.g., definitive agreement, proxy statements, or financial disclosures) for material terms and financial effects.